Literature DB >> 21164510

Drug discovery: New Btk inhibitor holds promise.

Rudi W Hendriks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21164510     DOI： 10.1038/nchembio.502

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN： 1552-4450            Impact factor:   15.040


× No keyword cloud information.
  9 in total

Review 1.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

2.  An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

Authors:  Michael E Weinblatt; Arthur Kavanaugh; Mark C Genovese; Theresa K Musser; Elliott B Grossbard; Daniel B Magilavy
Journal:  N Engl J Med       Date:  2010-09-22       Impact factor: 91.245

Review 3.  Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.

Authors:  M J Leandro; I de la Torre
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 4.  B cell signaling and tumorigenesis.

Authors:  Hassan Jumaa; Rudolf W Hendriks; Michael Reth
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

5.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

6.  Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

Authors:  Julie A Di Paolo; Tao Huang; Mercedesz Balazs; James Barbosa; Kai H Barck; Brandon J Bravo; Richard A D Carano; James Darrow; Douglas R Davies; Laura E DeForge; Lauri Diehl; Ronald Ferrando; Steven L Gallion; Anthony M Giannetti; Peter Gribling; Vincent Hurez; Sarah G Hymowitz; Randall Jones; Jeffrey E Kropf; Wyne P Lee; Patricia M Maciejewski; Scott A Mitchell; Hong Rong; Bart L Staker; J Andrew Whitney; Sherry Yeh; Wendy B Young; Christine Yu; Juan Zhang; Karin Reif; Kevin S Currie
Journal:  Nat Chem Biol       Date:  2010-11-28       Impact factor: 15.040

7.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Authors:  R Eric Davis; Vu N Ngo; Georg Lenz; Pavel Tolar; Ryan M Young; Paul B Romesser; Holger Kohlhammer; Laurence Lamy; Hong Zhao; Yandan Yang; Weihong Xu; Arthur L Shaffer; George Wright; Wenming Xiao; John Powell; Jian-Kang Jiang; Craig J Thomas; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Nathalie A Johnson; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Dennis D Weisenburger; Wing C Chan; Susan K Pierce; Louis M Staudt
Journal:  Nature       Date:  2010-01-07       Impact factor: 49.962

8.  Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation.

Authors:  U D Bajpai; K Zhang; M Teutsch; R Sen; H H Wortis
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

9.  Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement.

Authors:  J B Petro; S M Rahman; D W Ballard; W N Khan
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307
  9 in total
  20 in total

Review 1.  Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification.

Authors:  Elaine S Jaffe; Stefania Pittaluga
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  [Intracellular signaling transduction pathways. Potential targets in the treatment of rheumatic diseases].

Authors:  K W Frommer; M Geyer; G S Firestein
Journal:  Z Rheumatol       Date:  2012-08       Impact factor: 1.372

3.  Bruton tyrosine kinase (Btk) suppresses osteoblastic differentiation.

Authors:  Shoichi Kaneshiro; Kosuke Ebina; Kenrin Shi; Kiyoshi Yoshida; Dai Otsuki; Hideki Yoshikawa; Chikahisa Higuchi
Journal:  J Bone Miner Metab       Date:  2014-09-18       Impact factor: 2.626

Review 4.  New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.

Authors:  Robert C Rickert
Journal:  Nat Rev Immunol       Date:  2013-08       Impact factor: 53.106

5.  Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

Authors:  Yu-Tzu Tai; Betty Y Chang; Sun-Young Kong; Mariateresa Fulciniti; Guang Yang; Yolanda Calle; Yiguo Hu; Jianhong Lin; Jian-Jun Zhao; Antonia Cagnetta; Michele Cea; Michael A Sellitto; Mike Y Zhong; Qiuju Wang; Chirag Acharya; Daniel R Carrasco; Joseph J Buggy; Laurence Elias; Steven P Treon; William Matsui; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2012-06-11       Impact factor: 22.113

Review 6.  Neuropsychiatric lupus: new mechanistic insights and future treatment directions.

Authors:  Noa Schwartz; Ariel D Stock; Chaim Putterman
Journal:  Nat Rev Rheumatol       Date:  2019-03       Impact factor: 20.543

7.  SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.

Authors:  Linfeng Chen; Stefano Monti; Przemyslaw Juszczynski; Jing Ouyang; Bjoern Chapuy; Donna Neuberg; John G Doench; Agata M Bogusz; Thomas M Habermann; Ahmet Dogan; Thomas E Witzig; Jeffery L Kutok; Scott J Rodig; Todd Golub; Margaret A Shipp
Journal:  Cancer Cell       Date:  2013-06-10       Impact factor: 31.743

8.  Nonreceptor tyrosine kinases ITK and BTK negatively regulate mast cell proinflammatory responses to lipopolysaccharide.

Authors:  Weishan Huang; J Luis Morales; Victor P Gazivoda; Avery August
Journal:  J Allergy Clin Immunol       Date:  2015-11-12       Impact factor: 10.793

Review 9.  The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.

Authors:  J Eswaran; P Sinclair; O Heidenreich; J Irving; L J Russell; A Hall; D P Calado; C J Harrison; J Vormoor
Journal:  Leukemia       Date:  2015-05-06       Impact factor: 11.528

Review 10.  The C-kit receptor-mediated signal transduction and tumor-related diseases.

Authors:  Jing Liang; Yan-Ling Wu; Bing-Jia Chen; Wen Zhang; Yoshimasa Tanaka; Hiroshi Sugiyama
Journal:  Int J Biol Sci       Date:  2013-05-08       Impact factor: 6.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.